Bispecifics in Relapsed/ Refractory Multiple Myeloma: Combination Strategies, Stepping Up, and Treatment Dose Considerations
Panelists discuss the rationale behind combination strategies with bispecifics in relapsed/refractory multiple myeloma (R/R MM), highlighting key studies such as RedirecTT-1 for teclistamab and talquetamab, TRIMM-2 for talquetamab and daratumumab, and MagnetisMM-32 for elranatamab, along with considerations for step-up dosing and outpatient administration protocols.
Video content above is prompted by the following:
Let’s transition to recent updates on combination strategies with bispecifics in R/R MM: What is the rationale for these combination approaches?
- RedirecTT-1 for teclistamab andtalquetamab in R/R MM (Cohen et al. IMS 2024. Abstract OA-03/Cohen Y, J Clin Oncol 2023)
- TRIMM-2 for talquetamab anddaratumumab in R/R MM (Bahlis et al. IMS 2024. Abstract OA-01. /Dholaria B, J Clin Oncol 2023)
- MagnetisMM-32 for elranatamab vs EPd, PVd or Kd (Steven Schuster et al, ASCO 2024 Abstract TPS7576)
- How are the step-up and treatment doses for bispecifics administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for cytokine release syndrome and immune cell-associated neurotoxicity syndrome during step-up dosing?
- Please comment on the following studies examining outpatient administration of bispecifics and how these strategies might be incorporated in practice:
- OPTec: Outpatient Step-Up Administration of Teclistamab
- Ambulatory Teclistamab Administration in R/R MM
- What does the process look like for step-up dosing, treatment doses, and monitoring? Are there any variations?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
